Mirati Therapeutics Inc (MRTX) Major Shareholder Boxer Capital, Llc Sells 425,000 Shares

Mirati Therapeutics Inc (NASDAQ:MRTX) major shareholder Boxer Capital, Llc sold 425,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $69.00, for a total value of $29,325,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Boxer Capital, Llc also recently made the following trade(s):

  • On Thursday, January 17th, Boxer Capital, Llc purchased 150,000 shares of Mirati Therapeutics stock. The stock was acquired at an average cost of $62.00 per share, with a total value of $9,300,000.00.
  • On Tuesday, January 8th, Boxer Capital, Llc sold 550,000 shares of Mirati Therapeutics stock. The stock was sold at an average price of $52.10, for a total value of $28,655,000.00.

Shares of NASDAQ:MRTX traded down $0.74 during trading on Tuesday, hitting $72.19. The stock had a trading volume of 862,517 shares, compared to its average volume of 724,550. Mirati Therapeutics Inc has a 12-month low of $24.65 and a 12-month high of $79.31. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of -22.63 and a beta of 2.14.

Several brokerages have weighed in on MRTX. Jefferies Financial Group reissued a “hold” rating and issued a $37.00 price target on shares of Mirati Therapeutics in a report on Thursday, November 15th. Zacks Investment Research downgraded Mirati Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 15th. BidaskClub upgraded Mirati Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 7th. restated a “buy” rating and issued a $57.00 price objective (down from $62.00) on shares of Mirati Therapeutics in a research note on Tuesday, November 6th. Finally, B. Riley assumed coverage on Mirati Therapeutics in a research note on Friday, November 30th. They issued a “buy” rating and a $60.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Mirati Therapeutics has a consensus rating of “Buy” and an average target price of $63.64.

Several large investors have recently made changes to their positions in MRTX. FMR LLC raised its stake in shares of Mirati Therapeutics by 67.5% in the second quarter. FMR LLC now owns 1,986,315 shares of the biotechnology company’s stock worth $97,926,000 after purchasing an additional 800,223 shares during the last quarter. BlackRock Inc. raised its position in Mirati Therapeutics by 30.0% during the fourth quarter. BlackRock Inc. now owns 2,052,949 shares of the biotechnology company’s stock valued at $87,086,000 after acquiring an additional 474,097 shares in the last quarter. Credit Suisse AG raised its position in Mirati Therapeutics by 1,682.9% during the third quarter. Credit Suisse AG now owns 449,408 shares of the biotechnology company’s stock valued at $21,167,000 after acquiring an additional 424,202 shares in the last quarter. Jennison Associates LLC raised its position in Mirati Therapeutics by 62.4% during the third quarter. Jennison Associates LLC now owns 998,504 shares of the biotechnology company’s stock valued at $47,030,000 after acquiring an additional 383,785 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in Mirati Therapeutics by 54.9% during the third quarter. Janus Henderson Group PLC now owns 1,025,767 shares of the biotechnology company’s stock valued at $48,314,000 after acquiring an additional 363,728 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Mirati Therapeutics Inc (MRTX) Major Shareholder Boxer Capital, Llc Sells 425,000 Shares” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://sportsperspectives.com/2019/03/06/mirati-therapeutics-inc-mrtx-major-shareholder-boxer-capital-llc-sells-425000-shares.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.

Recommended Story: Lock-Up Period Expiration

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.